Viewpoints

Genetic Mutations and Prostate Cancer: Screening Recommendations In light of recently published data, Dr David Graham suggests potential approaches to prostate cancer screening that incorporate genetic test results.
Experts And Viewpoints, March 14, 2018
Social Media in Oncology: Does It Help Patients? Dr David Graham outlines a new effort among cancer specialists to determine whether social media improves either patient care or outcomes.
Experts And Viewpoints, May 03, 2016
Your Daily 'Miracle Cure' for Cancer Dr Jack West discusses the harm caused by hyperbole in news reports about cancer research, and the steps oncologists can take to prevent it.
Experts And Viewpoints, May 02, 2016
'Disturbing' Disparity in Use of Key Breast Cancer Drug A study indicates that black patients with HER2+ breast cancer are 25% less likely to receive trastuzumab than are white patients--an underuse that may affect outcomes, reports Dr Lidia Schapira.
Experts And Viewpoints, April 25, 2016
Reading Deeper: When Study Design Matters It is critical to assess a trial's design, and the assumptions inherent in that design, when comparing outcomes across trials, says Dr David Graham.
Experts And Viewpoints, April 05, 2016
PFS No Surrogate for OS in Metastatic Breast Cancer Trials A meta-analysis looked at whether progression-free survival can serve as a surrogate endpoint for overall survival in metastatic HER2+ breast cancer -- and the answer is no, reports Dr Lidia Schapira.
Experts And Viewpoints, March 18, 2016
'Failing Fast' and Moving Forward in Clinical Cancer Research The goal of clinical research in cancer should not be to conduct trials the fastest or achieve the largest number of positive trials at all costs, argues Dr Jack West.
Experts And Viewpoints, March 14, 2016
From Complexity to Precision in HR+ Breast Cancer Next-generation profiling shows HR+ advanced breast cancers to be heterogeneous, but may help identify the most appropriate and effective regimen for each patient, comments Dr Lidia Schapira.
Experts And Viewpoints, February 23, 2016
Comparing First-Line TKI Options for EGFR-Positive NSCLC Are there clinically significant differences among first-line EGFR TKI options for EGFR mutation-positive NSCLC?
Article, February 10, 2016
ALTTO No More Than a Detour for HER2+ Breast Cancer Dr Lidia Schapira weighs in on the results of the ALTTO trial in HER2-positive breast cancer in which dual therapy using trastuzumab plus lapatinib proved disappointing.
Experts And Viewpoints, January 25, 2016
The Distinct Profile of Lung Cancer in Young Patients Do young patients with lung cancer represent a distinct patient subgroup? Dr Jack West comments on a new study exploring this question.
Experts And Viewpoints, January 21, 2016
Leveraging Technology to Make the Most of a Scientific Meeting Dr David Graham discusses the advantages of using social media, and specifically Twitter, at medical conferences.
Experts And Viewpoints, January 15, 2016
Acquired Resistance in EGFR NSCLC: The Role of Repeat Biopsy Dr H. Jack West discusses new treatment options for EGFR-positive non-small cell lung cancer, including the emerging role of repeat biopsies among patients with acquired resistance.
Experts And Viewpoints, January 11, 2016
NSCLC: A Tale of Two Checkpoint Inhibitors Dr H. Jack West looks at recent data for both nivolumab and pembrolizumab for non-small cell lung cancer and discusses how he plans to use these agents in his clinic.
Experts And Viewpoints, October 21, 2015
New Option Emerging for Refractory mCRC Dr Alok Khorana comments on a novel agent that improves survival in refractory metastatic colorectal cancer.
Experts And Viewpoints, August 21, 2015
Palliative Care: A Primer for Oncologists 'You cannot be an oncologist and not do primary palliative care,' says Dr Jennifer Temel, who advises clinicians on delivering tough messages and when to seek help from palliative care specialists.
Experts And Viewpoints, August 10, 2015
Immunotherapy in Previously Treated Advanced NSCLC Dr Jack West provides an analysis of practice-changing studies presented at ASCO 2015, with a focus on lung cancer.
Experts And Viewpoints, July 31, 2015
Neratinib Lowers Recurrence in High-Risk HER2+ Breast Cancer Dr Lidia Schapira gives the take-home messages from breast cancer sessions of ASCO 2015, including top studies in HER2+ and HR+ disease, and new findings for managing side effects of treatment.
Experts And Viewpoints, June 15, 2015
Genomic Sequencing: Refining Lung Cancer Staging Dr Jack West comments on a very provocative proof of principle demonstrating the effect next-generation sequencing may have on tumor staging.
Experts And Viewpoints, May 19, 2015
RTOG 0617 Trial: With Chest Radiation, More Is Not Better Dr Jack West discusses two studies that challenge the prevailing presumption that in cancer treatment 'more must be better' and that underscore the value of clinical trials that refute these presumptions.
Experts And Viewpoints, April 27, 2015

No Results